Monoclonal antibody therapy for breast cancer: Herceptin
- 1 January 2003
- book chapter
- review article
- Published by Elsevier BV
- Vol. 21, 223-233
- https://doi.org/10.1016/s0921-4410(03)21010-3
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene, 1998
- Relative to any nonrecursive setProceedings of the American Mathematical Society, 1998
- Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.The EMBO Journal, 1995
- Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodiesCancer Immunology, Immunotherapy, 1993
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 CellsScience, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987